Litigation Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE, INC., USA (S.D. Ind. 2012)

« Back to Dashboard

ELI LILLY AND COMPANY v. ACCORD HEALTHCARE, INC., USA (S.D. Ind. 2012)

Docket	1:12-cv-00086	Date Filed	2012-01-20
Court	District Court, S.D. Indiana	Date Terminated	2017-08-11
Cause	35:271 Patent Infringement	Assigned To	Tanya Walton Pratt
Jury Demand	None	Referred To	Matthew Brookman
Patents	7,772,209
Link to Docket	External link to docket

Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE, INC., USA (S.D. Ind. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-01-20				External link to document

Eli Lilly v. Accord Healthcare Patent Litigation: Alimta Pemetrexed ANDA Case Analysis

Last updated: August 31, 2026

Eli Lilly and Company sued Accord Healthcare, Inc. in the District of Delaware after Accord filed an Abbreviated New Drug Application for a generic version of Alimta, Lilly’s pemetrexed product. The dispute centered on U.S. Patent No. 7,772,209, which covers administering pemetrexed with vitamin supplementation to reduce treatment-related toxicity.

The case was part of Lilly’s broader Alimta patent campaign against generic-drug applicants. The litigation ended through a settlement and dismissal rather than a reported trial judgment. Accord’s settlement terms were not publicly disclosed, but the case contributed to Lilly’s ability to delay generic competition until the expiration of the asserted Alimta method-of-use patent.

What drug and patent were involved in Eli Lilly v. Accord Healthcare?

The case involved Alimta, whose active ingredient is pemetrexed disodium. Alimta is an intravenous antifolate used primarily with platinum chemotherapy for non-small-cell lung cancer and malignant pleural mesothelioma.

Lilly asserted U.S. Patent No. 7,772,209, titled “Methods of Administering Pemetrexed.” The patent covers administering pemetrexed to a patient who has received folic acid and vitamin B12 supplementation. The supplementation regimen reduces hematologic and gastrointestinal toxicity associated with pemetrexed treatment.

Item	Details
Brand	Alimta
Active ingredient	Pemetrexed disodium
Dosage form	Intravenous injection or infusion
NDA holder	Eli Lilly and Company
Defendant	Accord Healthcare, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:12-cv-00086
Primary patent	U.S. Patent No. 7,772,209
Patent type	Method of treatment and vitamin-supplementation regimen
Regulatory trigger	Accord ANDA filing for generic pemetrexed
Resolution	Settlement and dismissal

The case did not primarily concern Lilly’s original pemetrexed compound patent. It concerned the later vitamin-supplementation patent, which extended practical protection for Alimta after the compound patent approached expiration.

What was the litigation timeline in Eli Lilly v. Accord Healthcare?

Lilly filed the action in 2012 after receiving notice of Accord’s ANDA certification. The lawsuit triggered the Hatch-Waxman statutory stay, preventing FDA approval of Accord’s ANDA for up to 30 months unless the case was resolved earlier.

Key procedural events

Date or period	Event
2012	Lilly filed the patent infringement action against Accord in the District of Delaware.
2012	The case was assigned civil action number 1:12-cv-00086.
2012-2014	The parties litigated Lilly’s patent claims and Accord’s validity and noninfringement defenses.
2014	Lilly and Accord resolved the dispute through a settlement.
2014	The action was dismissed pursuant to the settlement.
2021-2022	The asserted Alimta method-of-use patent reached the end of its effective term, subject to applicable patent-term and pediatric-exclusivity calculations.
2022 onward	Generic pemetrexed competition expanded after the relevant Alimta patent barriers ended.

The public docket reflects a terminated ANDA litigation rather than a final merits decision determining that Accord infringed a valid patent. The settlement therefore provides limited precedent on the ultimate validity of the ’209 patent as against Accord.

What were Accord’s Paragraph IV patent challenges?

Accord’s ANDA filing appears to have included a Paragraph IV certification directed to Lilly’s listed Alimta patent. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Lilly’s complaint alleged that Accord’s proposed product would infringe claims of the ’209 patent. Accord could contest the case through several standard Hatch-Waxman defenses:

• The proposed product would not infringe the claimed vitamin-supplementation regimen.
• The asserted claims were invalid for lack of novelty or obviousness.
• The patent specification did not adequately support the asserted claims.
• The patent was unenforceable because of inequitable conduct or another litigation defense.
• The proposed label did not induce infringement.

The most important legal issue in the broader pemetrexed litigation was whether the claimed vitamin regimen was sufficiently described and nonobvious. Lilly successfully defended the ’209 patent in related litigation against other generic applicants, including Teva. Those decisions strengthened Lilly’s negotiating position in settlements with other ANDA filers. [1]

How strong was Lilly’s Alimta patent estate?

Lilly’s Alimta estate was commercially strong because it combined several layers of protection:

1. An original compound patent covering pemetrexed.
2. A formulation and pharmaceutical-composition portfolio.
3. A method-of-use patent covering vitamin supplementation.
4. FDA Orange Book listings that required generic applicants to address the patents in their ANDAs.
5. Litigation precedent supporting the validity and enforceability of the vitamin-regimen claims.

Primary Alimta patent layers

Patent layer	Commercial function	Strategic value
Compound patent	Protected pemetrexed itself	Blocked direct generic substitution during the compound term
Formulation patents	Covered injectable compositions and pharmaceutical formulations	Created additional technical infringement theories
Method-of-use patent	Required folic acid and vitamin B12 supplementation	Extended protection beyond the compound patent
Regulatory listing	Placed relevant patents in the Orange Book	Forced ANDA applicants to make patent certifications
Litigation record	Federal Circuit decisions upheld key claims	Increased settlement leverage

The ’209 patent was particularly important because the vitamin regimen became part of standard Alimta prescribing practice. That made a clean “skinny label” strategy more difficult than in a case involving an optional or commercially insignificant indication.

What was the Orange Book status of Alimta?

The FDA Orange Book listed Alimta-related patents, including the ’209 patent, during the period relevant to Accord’s ANDA. The listings required generic applicants to address Lilly’s patent rights through Paragraph I, II, III, or IV certifications, depending on the patent’s status.

The Orange Book did not create patent rights. It connected Lilly’s listed patents to FDA approval procedures and imposed the statutory framework for ANDA patent disputes.

Orange Book and FDA implications

• Accord could not obtain ordinary ANDA approval without addressing the listed patents.
• A Paragraph IV notice gave Lilly a basis to file an infringement action.
• Lilly’s complaint triggered the statutory approval stay.
• Settlement terms could include a negotiated generic-entry date.
• FDA approval remained subject to regulatory, labeling, bioequivalence, and manufacturing requirements independent of patent litigation.

The relevant Alimta patent barriers later expired. Current generic pemetrexed products are therefore evaluated primarily on FDA approval, supply, manufacturing, pricing, and market-access factors rather than on the expired ’209 patent.

What was the settlement and when could Accord launch?

The case ended by settlement, and the public record does not disclose the complete economic or commercial terms. Hatch-Waxman settlements commonly specify:

• A licensed or permitted generic-entry date.
• Whether the defendant may launch an authorized generic.
• Restrictions on challenging the patent.
• Supply or distribution arrangements.
• Terms governing pediatric exclusivity.
• Treatment of future patent rights.

Accord’s precise contractual launch date and any compensation terms should not be inferred solely from the dismissal entry. The case’s commercial effect was to defer an immediate generic launch while preserving a negotiated pathway for entry after Lilly’s remaining Alimta patent protection.

The settlement must also be distinguished from a judgment. There was no reported final decision in this action holding that Accord’s ANDA product infringed the ’209 patent after trial.

What patent litigation affected Alimta generic entry?

Lilly brought related cases against multiple generic applicants. The broader litigation mattered because decisions involving one ANDA defendant affected the bargaining position of all parties.

Related Alimta litigation

The most significant reported decision was Eli Lilly v. Teva Parenteral Medicines, in which the Federal Circuit upheld the ’209 patent against validity and infringement challenges. The court rejected arguments that the vitamin-supplementation regimen was obvious and affirmed Lilly’s protection for the claimed treatment method. [1]

Other Alimta defendants included generic manufacturers and distributors that filed ANDAs for pemetrexed products. Lilly used the same core patent strategy across the litigation group, although each case depended on the defendant’s ANDA, proposed label, product formulation, and defenses.

The Accord action therefore has greater commercial significance as part of the coordinated Alimta ANDA campaign than as an independent source of precedent.

Did the case create biosimilar risk for Alimta?

No. Alimta is a conventional small-molecule drug, not a biologic. Generic pemetrexed applicants use the ANDA pathway under the Hatch-Waxman Act. The Biologics Price Competition and Innovation Act and biosimilar procedures do not apply.

Issue	Alimta
Product category	Small-molecule oncology drug
FDA pathway	ANDA for generic versions
Biosimilar pathway	Not applicable
Main regulatory test	Pharmaceutical equivalence and bioequivalence
Patent mechanism	Orange Book certifications and Hatch-Waxman litigation

The competitive risk came from generic injectable pemetrexed, not biosimilar pemetrexed.

What formulation patents and manufacturing barriers remained?

The ’209 patent was a method-of-use patent, not a complete manufacturing barrier. A generic manufacturer also had to develop a commercially acceptable sterile injectable product, demonstrate bioequivalence or relevant pharmaceutical equivalence, satisfy current good manufacturing practice requirements, and obtain FDA approval.

Potential technical barriers included:

• Sterile manufacturing and aseptic processing.
• Control of degradation and impurities.
• Stability of the injectable formulation.
• Container-closure compatibility.
• Reconstitution and infusion instructions.
• Consistency of active-ingredient content.
• Supply of pharmaceutical-grade pemetrexed.
• Compliance with oncology-product manufacturing standards.

These requirements could delay commercial launch but did not provide Lilly with the same exclusionary rights as an unexpired patent. After patent expiry, manufacturing execution and cost structure became the principal barriers.

How did Lilly’s Alimta estate compare with competing oncology drug estates?

Lilly’s strategy resembled the estate structure used for other high-value oncology products: an early composition-of-matter patent followed by later formulation, dosing, and method-of-use rights.

Factor	Alimta	Typical competing oncology product
Core protection	Compound patent followed by regimen patent	Often compound plus indication patents
Product type	Small-molecule injectable	Small molecule, biologic, or antibody
Generic pathway	ANDA	ANDA for small molecules; biosimilar pathway for biologics
Key late-life protection	Vitamin-supplementation method	Dosing, combination, formulation, or biomarker claims
Litigation leverage	Strong due to standard-of-care regimen	Depends on label and claim coverage
Manufacturing complexity	Sterile injectable	Often higher for biologics
Biosimilar exposure	None	Material for biologic oncology products

Alimta’s late-life patent position was stronger than a simple compound-only estate because the vitamin regimen was integrated into clinical practice. That integration also created a potential induced-infringement issue for generic labels.

What generic entry risks existed for Lilly?

Lilly faced several distinct entry scenarios:

Early entry after Paragraph IV success

If Accord had prevailed on invalidity or noninfringement, FDA approval could have followed after resolution of the statutory stay and satisfaction of regulatory requirements.

Entry after settlement

This was the outcome in the Accord case. The parties avoided a final merits judgment and established a negotiated path to market entry.

Launch after patent expiry

Once the relevant patent and exclusivity periods ended, generic pemetrexed applicants could enter without relying on a settlement license.

At-risk launch

A generic applicant could launch before final resolution of all patent issues, accepting potential damages and injunction risk. There is no indication that Accord pursued an at-risk launch in this case.

What was the revenue exposure from the Accord case?

Alimta was one of Lilly’s major oncology products before generic erosion. The product generated multibillion-dollar annual sales at its peak and remained commercially important as the company managed the transition to post-patent competition.

The Accord litigation affected:

• The timing of generic price erosion.
• Lilly’s ability to preserve branded Alimta sales.
• Settlement economics with multiple ANDA applicants.
• Forecasts for oncology revenue after compound-patent expiry.
• The value of Lilly’s later-life patent portfolio.

Once several generic pemetrexed suppliers entered, market share and net pricing were expected to decline rapidly. Injectable oncology products can experience sharp erosion when multiple approved generics compete, although hospital contracting, supply reliability, and shortage conditions can moderate the pace.

What is the current litigation status of Eli Lilly v. Accord?

The case is closed. It was resolved through settlement and dismissal, not through a publicly reported final trial judgment. The ’209 patent and associated Alimta exclusivity period have expired, so the action no longer presents an active patent injunction risk to Accord’s generic pemetrexed business.

The case remains relevant for three reasons:

1. It documents Lilly’s use of a vitamin-regimen patent to extend Alimta protection.
2. It forms part of the broader pemetrexed Paragraph IV litigation record.
3. It illustrates the commercial value of method-of-use claims when the claimed regimen is incorporated into the standard product label.

Key Takeaways

• Eli Lilly sued Accord over an ANDA for generic pemetrexed, the active ingredient in Alimta.
• The principal asserted patent was U.S. Patent No. 7,772,209.
• The patent covered vitamin supplementation before and during pemetrexed treatment.
• The case was filed in the District of Delaware in 2012 under No. 1:12-cv-00086.
• The litigation ended through settlement and dismissal rather than a reported merits judgment.
• Related litigation against Teva upheld the ’209 patent and improved Lilly’s settlement leverage.
• The case involved a small-molecule generic, not a biosimilar.
• Generic entry risk became material after expiration of the relevant patent and exclusivity periods.
• Lilly’s commercial protection depended on a layered Alimta estate, with the vitamin-regimen patent providing important late-life coverage.

FAQs About Eli Lilly v. Accord Healthcare

What was Accord’s generic product in the Lilly lawsuit?

Accord sought approval for generic pemetrexed, the injectable antifolate marketed by Lilly as Alimta.

Which Lilly patent was challenged by Accord?

The principal patent was U.S. Patent No. 7,772,209, covering administration of pemetrexed with folic acid and vitamin B12 supplementation.

Did Eli Lilly win a trial against Accord?

No reported merits judgment followed in the Accord action. The parties resolved the dispute through settlement and the case was dismissed.

Was Accord allowed to launch generic Alimta before patent expiry?

The settlement established a negotiated entry framework. The complete commercial terms and precise contractual launch provisions were not publicly disclosed in the court’s dismissal record.

Does the Lilly v. Accord case affect current pemetrexed approvals?

The case does not create an active patent barrier today. Current generic pemetrexed competition is governed primarily by FDA approval, manufacturing capability, pricing, and supply conditions.

References

1. Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 689 F.3d 1368 (Fed. Cir. 2012).

2. Eli Lilly & Co. v. Accord Healthcare, Inc., No. 1:12-cv-00086, U.S. District Court for the District of Delaware, docket filings and dismissal record.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,772,209: Methods of administering pemetrexed. U.S. Department of Commerce.

5. Eli Lilly and Company. (Various years). Annual reports and Form 10-K filings. U.S. Securities and Exchange Commission.